N/A N=4,749,072 TB Innovation Project: A Pre- and Post- Implementation Assessment (TIPPI)
Tuberculosis · Pediatric
Primary: Children Screened for TB — 4749072 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=31 Single Fraction Elderly Breast Irradiation (SiFEBI)
Breast Cancer
Primary: Rate of Acute Toxicity Within 180 Days of IPAS Mono Split Postoperatively in Patients Aged at Least of 70 Years With Breast Cancer at Low Risk of Local Recurrence (Low…
Phase 2 N=22 Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis
Dermatitis, Allergic Contact
Primary: Number of Participants With Positive Reaction Scores Based Upon ICDRG Scoring Scale: Regimen 1 — 5; 9 Participants
N/A N=29 AdheRence to Inhaled Corticosteroids in Asthma
Medication Adherence · Asthma
Primary: Number of Participants Who Reported Experiences With the ARICA Program — 12 Participants
Phase 3 N=631 Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 — 15.1; 50.0; 53.8 percentage of participants — p=< 0.0001
N/A N=69 Physical Therapist as Primary Assessor for Patients With Knee Pain in Primary Care
Knee Osteoarthritis
Primary: Change From Health Related Quality of Life (HrQoL) at 12 Months - EQ5D-index — 0.804; 0.825 score on a scale — p=0.87
Phase 2 N=219 A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Carcinoma, Transitional Cell · Urinary Bladder Neoplasms · Urologic Neoplasms
Primary: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) — 44; 51.7 Percentage of Participants
Phase 3 N=618 TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
Atopic Dermatitis
Primary: VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 — 7.6; 39.0; 51.3 percentage of participants…
Phase 2 N=10 Effect of Increasing Doses of Tiopronin on Cystine Capacity in Patients With Cystinuria
Cystinuria
Primary: Change in Cystine Capacity From Baseline — -63.6; 76; 53.4; 103.1 mg/L
Phase 2 N=10 Trial of Rifaximin in Probable Alzheimer's Disease
Alzheimer's Disease
Primary: Number of Participants Experiencing Diarrhea Caused by Clostridium Difficile — 5 Participants
Phase 2 N=123 Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia
Primary Ciliary Dyskinesia
Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs — 52; 46; 22; 23 Participants
Phase 2 N=50 FARE Peanut SLIT and Early Tolerance Induction
Peanut Hypersensitivity · Food Allergy · Food Hypersensitivity
Primary: Desensitization After 36 Months of Peanut SLIT or Placebo SLIT — 4.9; 2.5 score on a scale — p=0.002
Phase 4 N=93 Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases
Systemic Lupus Erythematosus (SLE) · Juvenile SLE · Cutaneous Lupus
Primary: Serum Levels of Thalidomide — 415.1 ng/mL
Phase 3 N=829 Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)
COVID-19 · Corona Virus Infection · SARS (Severe Acute Respiratory Syndrome)
Primary: Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection — 45; 53 Participants
Phase 2 N=43 BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
Muscle Invasive Bladder Cancer
Primary: Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging…